MARKET

CFRX

CFRX

ContraFect
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.61
+0.27
+5.06%
Closed 18:10 10/28 EDT
OPEN
5.24
PREV CLOSE
5.34
HIGH
5.62
LOW
5.16
VOLUME
116.53K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
2.900
MARKET CAP
156.01M
P/E (TTM)
-1.7050
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),
Benzinga · 2d ago
We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 10/01 12:31
ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference
YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening
GlobeNewswire · 09/09 12:30
ContraFect secures research funding from Cystic Fibrosis Foundation
ContraFect (CFRX +1.0%) has entered into an initial funding agreement with the Cystic Fibrosis Foundation to investigate the potential utility of direct ly
Seeking Alpha - Article · 08/25 16:05
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
GlobeNewswire · 08/25 12:30
CFRX: Enrollment Continues in Phase 3 Trial of Exebacase
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect announced the first patient had been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with
Zacks Small Cap Research · 08/19 10:50
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Pulse Biosciences (PLSE): $250M.ContraFect (CFRX): $150M.Larimar Therapeutics (LRMR): $200M.
Seekingalpha · 08/15 22:07
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
GlobeNewswire · 08/14 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CFRX. Analyze the recent business situations of ContraFect through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CFRX stock price target is 15.67 with a high estimate of 22.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 20.98M
% Owned: 75.45%
Shares Outstanding: 27.81M
TypeInstitutionsShares
Increased
17
5.32M
New
33
4.34M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Chief Executive Officer/Director
Roger Pomerantz
Chief Financial Officer/IR Contact Officer
Michael Messinger
Executive Vice President
Cara Cassino
Vice President - Finance
Nancy Dong
Vice President
Jane Ambler
General Counsel/Secretary
Natalie Bogdanos
Lead Director
Sol Barer
Director
Lishan Aklog
Independent Director
David Low
Independent Director
Michael Otto
Independent Director
Cary Sucoff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CFRX
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ContraFect Corp stock information, including NASDAQ:CFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CFRX stock methods without spending real money on the virtual paper trading platform.